Prevention and management of hand-foot skin reaction induced by multitargeted tyrosine kinase inhibitors^[1-4]

NSAID: nonsteroidal anti-inflammatory drug; GABA: gamma-aminobutyric acid; TKI: tyrosine kinase inhibitor; HFSR: hand-foot skin reaction.

References:

McLellan B, Ciardiello F, Lacouture ME, et al. Regorafenib-associated hand-foot skin reaction: practical advice on diagnosis, prevention, and management. Ann Oncol 2015; 26:2017.
Lacouture ME, Wu S, Robert C, et al. Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist 2008; 13:1001.
Anderson R, Jatoi A, Robert C, et al. Search for evidence-based approaches for the prevention and palliation of hand-foot skin reaction (HFSR) caused by the multikinase inhibitors (MKIs). Oncologist 2009; 14:291.
Manchen E, Robert C, Porta C. Management of tyrosine kinase inhibitor-induced hand-foot skin reaction: viewpoints from the medical oncologist, dermatologist, and oncology nurse. J Support Oncol 2011; 9:13.

Graphic 109178 Version 4.0

Prevention and management of hand-foot skin reaction induced by multitargeted tyrosine kinase inhibitors[1-4]